Introduction
Gene therapy based on the transfer of a functional gene into a particular tissue to alleviate a genetic deficiency has emerged as an exciting form of molecular medicine. Several limitations hinder the efficiency of gene delivery in skeletal muscle. The low transfection efficiency continues to be the main obstacle confronting gene transfer based on nonviral vectors, although progress is being made on this front. [1] [2] [3] The efficiency of gene transfer mediated by viral vectors (adenovirus (AD), retrovirus (RSV), and herpes simplex virus (HSV) vectors) is limited due to immune rejection problems, cellular cytotoxicity related to viral transduction, and a poor level of viral transduction in adult muscle compared to that observed in newborn muscle. [4] [5] [6] [7] [8] Researchers have focused extensive effort on increasing the efficiency of gene transfer while decreasing the immunogenicity and the cellular cytotoxicity associated with viral infection. [4] [5] [6] [7] [8] In addition, other viral vectors, including the adeno-associated virus, have been used to deliver genes in skeletal muscle and have remedied some of the difficulties facing viral gene transfer to skeletal muscle. [9] [10] [11] [12] In light of these findings, the cellular cytotoxicity barriers associated with viral-mediated gene transfer have been fully characterized and can be partially circumvented; however, immune rejection continues to pose challenges that impede efficient gene transfer to skeletal muscle.
The selection of appropriate promoters that restrict transgene expression to specific tissues, such as skeletal muscle fibers, may also play an important role in improving the efficiency and persistence of transgene expression. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Ishii A et al found that injection of an AD in which the b-galactosidase reporter gene is under the bactin promoter with cytomegalovirus (CMV) enhancer (CAG) resulted in the transduction of up to 60% of the myofibers in the skeletal muscles of 5-to 6-week-old normal mice. 16 This finding implies that viral promoters may influence the level of adenoviral-mediated gene transfer in skeletal muscle. The use of viral promoters likely causes ubiquitous transgene expression in various cell types and tissues, and thus may lead to cytotoxicity and a systemic immune response directed against the viral vector or the transgene itself. 23 Researchers could prevent these side effects by developing methods to ensure tissue-specific transgene expression, perhaps by using transcriptional regulatory elements that are active only in the target tissue.
Several ADs that contain muscle-specific transcriptional regulatory elements have been reported. The muscle-specific expression of the transgene mediated by these vectors has resulted in improved persistence of transgene expression. 14, 15, 24 Recently, some researchers have used the muscle creatine kinase (MCK) promoter for muscle-specific gene transfer. 14, 15, 21 MCK, the most abundant nonmitochondrial mRNA, is expressed in all types of skeletal muscle fibers. 25 The MCK gene is not expressed in myoblasts, but becomes transcriptionally activated when myoblasts commit to terminal differentiation. 24, 26 Thus, using the MCK promoter to drive a transgene could restrict the transgene expression to differentiated myotubes and myofibers and prevent its expression in nondifferentiated myogenic cells and nonmuscle cells such as antigen-presenting cells (APCs). Such muscle-specific expression may help to limit the immune response associated with gene transfer to skeletal muscle.
Researchers have proposed ex vivo gene transfer based on genetically engineered myoblasts as an alternative approach for the treatment of muscle diseases, 4,27-31 but limitations similar to those associated with myoblast transplantation [32] [33] [34] [35] [36] [37] [38] also hinder the success of this technology. Recently, researchers have focused increasingly on the use of muscle-derived stem cells (MDSCs) in cell transplantation and ex vivo gene therapy applications aimed at gene transfer to skeletal muscle. [39] [40] [41] [42] [43] We have generated data that provide several lines of evidence supporting the existence of MDSCs that, in comparison to myoblasts, improve the outcome of transplantation in skeletal muscle. 27, 43, 44 We hypothesized that the use of a population of MDSCs would enhance the efficiency of ex vivo gene transfer to skeletal muscle.
Our study, presented here, investigated the ability of MDSC-based ex vivo gene transfer to ameliorate the efficiency of viral transduction of myofibers. This ex vivo gene transfer approach may also prevent the transduction of host APCs in the injected muscle. An ex vivo approach is advantageous because the viral transduction is carried out in vitro, allowing the transgene to be expressed specifically in the transduced cells, and thus avoiding viral transduction of nontargeted cells (eg APCs). Although this technique has been used to deliver genes in skeletal muscle, the long-term persistence of the transgene has been limited by the presence of an immune response. 31 We therefore hypothesized that the use of a viral vector that encodes for a given transgene under the control of a viral promoter may trigger an immune response because the transduced cells can act as APCs.
We first evaluated and compared the efficiency of gene transfer to mature skeletal muscle and the presence of an immune response after direct intramuscular injection of an AD encoding the luciferase gene under the CMV promoter (ADCMV) or an AD encoding the luciferase gene under the MCK promoter (ADMCK). We then used the ex vivo gene transfer approach based on MDSCs transduced with the adenoviral vectors (ADMCK and ADCMV) to determine whether the promoter is a major determinant in the persistence of transgene expression in skeletal muscle and to investigate whether adenovirally transduced MDSCs act as APCs when used as vehicles for ex vivo gene transfer to skeletal muscle.
Results

ADCMV and ADMCK transduction of mdx muscle
We injected the same titer of ADCMV and ADMCK into the hind limb muscles of 6-to 8-week-old mdx mice.
Examination for luciferase expression 7, 14, 30, and 60 days after injection indicated that both viruses were able to transduce muscle fibers within the injected mdx skeletal muscle (Figure 1a-g ). The transgene expression mediated by direct injection of ADCMV decreased dramatically within 30 days after injection (Figure 1g ). However, we observed better persistence of the transgene expression and significantly higher levels of transgene expression 30 and 60 days after injection in the muscles injected with ADMCK (Figure 1f and g ) than in those injected with ADCMV (Figure 1e and g ).
Immune response after viral injection
To elucidate the mechanism by which ADMCK injection resulted in better persistence of the transgene within the mdx skeletal muscle, we investigated the infiltration of lymphocytes within the injected muscle. Immunostaining for CD4 and CD8 cells revealed that ADCMV injection triggered a massive infiltration of CD4-and CD8-positive lymphocytes in the muscle at 7 days after injection; we detected fewer CD4-and CD8-positive lymphocytes in the muscle injected with ADMCK (data not shown). Even 60 days after injection, lymphocytes were present within the muscle injected with ADCMV, while very few lymphocytes were visible in the muscle injected with ADMCK (data not shown). By using an antibody against MHC class I and II, we observed massive expression of H-2K
b , H-2D b (MHC class I), and MHC class II in the muscle injected with ADCMV at 7 days after injection (Figure 2a-c) . We also examined a costimulatory molecule at the same time point and observed CD28 expression in the injection sites ( Figure  2d ). The existence of these molecules demonstrates that ADCMV injection triggered the immune response. In contrast, ADMCK injection led to significantly weaker expression of these molecules (Figure 2e-h ).
Ex vivo gene transfer mediated by adenovirally transduced MDSCs
We transduced MDSCs in vitro with ADCMV or ADMCK, and then performed immunostaining for luciferase by using a polyclonal rabbit anti-luciferase antibody. We detected luciferase expression in the nondifferentiated MDSCs transduced by ADCMV, but not in the MDSCs transduced with ADMCK (Figure 3a and c). However, we observed luciferase expression in myotubes in both groups (Figure 3b and d) . We then injected the same number of ADCMV-transduced MDSCs or ADMCK-transduced MDSCs into the gastrocnemius muscles of mdx mice.
Examination of the muscle sections at early time points (7 days after injection) revealed similar levels of transgene expression by both populations of virally transduced cells. However, at time points beyond 14 days after injection, the transgene expression decreased in the muscle injected with ADCMV-transduced MDSCs (Figures 4a and 5a ). Transgene expression was more persistent in the muscle injected with ADMCK-transduced MDSCs (Figures 4b and 5a) . 
Preinjection of ADCMV-transduced MDSCs significantly reduced the persistence of transgene expression after subsequent ADMCK injection
We first transduced MDSCs with either ADCMV or ADMCK, and then injected the transduced cells into mdx mouse skeletal muscles. We injected ADMCK into both groups of mice 1 week later. At 7 days after the second injection, the muscles first injected with ADCMV- Figure 1 Luciferase expression in the skeletal muscles of 6-to 8-week-old mdx mice, as determined by immunocytochemistry and luciferase assay. Immunocytochemical staining showed different numbers of myofibers expressing the luciferase transgene in ADCMV-injected muscle (a, c, e) and in ADMCK-injected muscle (b, d, f) at 7 (a, b), 14 (c, d), and 60 (e, f) days after injection. Luciferase assay revealed that ADMCK injection produced transgene expression that persisted 60 days after injection (g). In contrast, ADCMV injection resulted in high levels of transgene expression at days 7 and 14, but decreased levels thereafter (g). *Significant difference. Bar, 50 mm.
Muscle-specific promoter improves gene transfer to skeletal muscle B Cao et al transduced MDSCs exhibited lower transgene expression than did the muscles first injected with ADMCKtransduced MDSCs (Figures 7a and b) . The muscles first injected with ADMCK-transduced cells continued to exhibit higher transgene expression 30 days after subsequent injection with ADMCK when compared with the other experimental group (Figure 8a ). Immunostaining for CD4-and CD8-positive lymphocytes 7 and 30 days after the second injection indicated that the muscles preinjected with ADCMV-transduced cells (Figures 7c, e and 8b, c) displayed significantly greater lymphocyte infiltration than did the muscles preinjected with ADMCK-transduced cells (Figures 7d, f and 8b, c) . These results suggest that MDSCs can act as APCs when transduced with an AD that encodes for a reporter gene under the CMV promoter, but that the use of an AD that encodes the transgene under a muscle-specific promoter significantly reduces the immune response after subsequent injection of ADMCK.
MDSCs acquired the APC function after adenoviral transduction
We confirmed that nondifferentiated MDSCs transduced by ADCMV express luciferase in vitro, but MDSCs transduced by ADMCK do not. More importantly, a Muscle-specific promoter improves gene transfer to skeletal muscle B Cao et al functional DQ-Ovalbumin assay 45 revealed that ADCMV-transduced MDSCs acquired the antigen-processing function, but ADMCK-transduced MDSCs did not ( Figure 9 ). We did not detect dendritic cell antigen expression in the ADCMV-transduced MDSCs used for this study. Although this finding further supports the hypothesis that MDSCs transduced by ADCMV can act as APCs, we did not observe differentiation of the MDSCs into APCs.
Discussion
In this project, we demonstrated that the use of different promoters (CMV or MCK) within a given adenoviral construct affects the efficiency and the persistence of transgene expression after adenoviral-mediated gene transfer into the skeletal muscles of mdx mice. Both direct and ex vivo gene transfer of ADMCK triggered a lower immune response that led to more efficient and more persistent transgene expression when compared to the direct or ex vivo gene transfer of ADCMV. ADCMV injected directly into the skeletal muscle transduced resident APCs, which consequently expressed the transgene and rapidly induced an immune response. MDSCs transduced with ADCMV and delivered via ex vivo gene transfer acted as APCs after implantation in skeletal muscle. Our results suggest that the ADCMV-transduced MDSCs expressed the transgene, and therefore rapidly initiated an immune response, while the ADMCKtransduced MDSCs expressed the transgene only after differentiation into myotubes and myofibers, ultimately leading to longer persistence of the transgene in the injected skeletal muscle. These results taken together demonstrate that the use of a muscle-specific promoter to restrict the transgene expression to skeletal muscle can prevent MDSCs from acting as APCs, and thereby can improve both the efficiency and long-term benefits of gene transfer in skeletal muscle.
Host immune response constitutes a major problem for gene therapy applications, particularly in techniques that involve the use of first-generation adenoviral It thus makes sense that after direct injection into the muscle, ADCMV transduced both macrophages and dendritic cells (professional APCs), which consequently expressed the luciferase gene delivered under the control of the CMV promoter. Presentation of the transgene by the APCs then induced the immune response indicated by the large infiltration of CD4-and CD8-positive lymphocytes and the expression of MHC class I and II and a costimulatory molecule (CD28) within the injected muscle. Although the direct injection of ADMCK also likely led to the transduction of APCs, the transduced cells did not express the luciferase reporter gene because the MCK promoter restricts transgene expression to differentiated muscle cells. Therefore, the immune response was significantly reduced, leading to longer persistence of the transgene (Figure 10a ). Muscle-specific promoter improves gene transfer to skeletal muscle B Cao et al
Our second set of experiments involved the use of ex vivo gene transfer to investigate whether MDSCs can also act as APCs in skeletal muscle. The ex vivo approach enabled us to restrict the viral transduction to MDSCs in vitro and prevented the transduction of resident APCs within skeletal muscle in vivo. However, we still observed severe immune responses after injection of the ADCMV-transduced MDSCs into skeletal muscle. In light of these findings, we hypothesized that adenovirally transduced MDSCs may act as APCs after injection into mouse skeletal muscle. We already had determined (in a previous set of experiments) that MDSCs transplanted into lethally irradiated mice can differentiate into macrophages and toward other hematopoietic lineages, 47 a finding that suggests that MDSCs can differentiate into APCs. However, we did not detect dendritic cell antigen expression in the ADCMV-transduced MDSCs used in the current study. Although this finding suggests a lack of differentiation of MDSCs toward APCs, the in vitro DQ-Ovalbumin assay indicated that the MDSCs did act as APCs. Furthermore, other researchers have reported that human muscle cells can act as APCs. [48] [49] [50] In the present study, MDSCs transduced with ADCMV expressed the transgene and triggered lymphocyte infiltration. However, ADMCK-transduced MDSCs expressed the transgene only after differentiation, resulting in a significant reduction in the immune response ( Figure  10b) . Our data indicate, as previously observed with the direct gene transfer approach, that the use of a muscle differentiation-specific promoter is critical to minimize immune rejection of the transgene after ex vivo gene transfer to skeletal muscle. Our results also indicate that the luciferase released from dying ADCMV-transduced MDSCs was taken up by APCs, which presented it in the context of MHC I via the crosspresentation pathway. In contrast, dying ADMCK-transduced MDSCs did not release the antigen because these cells only expressed luciferase after differentiation into myotubes. Although Figure 10 Schematic representation of the different effects of ADCMV and ADMCK transduction. The upper panel (a) depicts the mechanism involved in direct viral injection. Both viruses transduce myogenic cells and APCs. After intramuscular injection, ADCMV-transduced host cells begin to express the transgene, and therefore trigger an immune response that eventually eliminates the transduced cells and myofibers. ADMCK-transduced cells express the transgene only after differentiation into myotubes and myofibers, and hence do not trigger a severe immune response. For the ex vivo approach (middle panel, b), injection of the ADCMV-transduced MDSCs triggered CD4-and CD8-positive cell infiltration (due to the expression of the transgene). This immune response significantly reduces the transduction efficiency and the persistence of the transgene expression. However, when ADMCK-transduced MDSCs are injected, the transgene is expressed only after the cells differentiate into myotubes. Hence, a decreased infiltration of CD4-and CD8-positive cells is observed and the transduced myofibers survive longer. Dead ADCMV-transduced cells may also release the antigen, which can help to elicit the immune response. Dead ADMCK-transduced cells, due to their lack of transgene expression, do not trigger an immune response via this mechanism. The ex vivo plus direct injection experiments further support the hypothesis that myogenic cells can act as APCs (lower panel, c). When ADCMV-transduced cells were injected into muscle, an immune response was observed. After the subsequent injection of ADMCK, the virus was rapidly rejected. However, when ADMCK-transduced cells were injected first, the transgene was not expressed in the cells until they differentiated into myotubes and myofibers; thus, a reduction in the immune response was observed. This behavior led to better persistence of transgene expression in the transduced muscle fibers after the second injection of ADMCK.
Muscle-specific promoter improves gene transfer to skeletal muscle B Cao et al by this mechanism ADCMV-transduced MDSCs are more likely to initiate an immune response than are ADMCK-transduced MDSCs, we still observed decreased transgene expression even when using ADMCK for the ex vivo gene transfer. We hypothesize that this decline in transgene expression may be attributable to necrosis of the dystrophin-deficient muscle fibers over time, although the decline could also be due to an immune response. The occurrence of an immune response would correlate with the results observed previously, which indicated that transgene expression driven by the MCK promoter can still cause an immune response, although it generally occurs at a later time point. 22 Such an immune response indicates that differentiated muscle fibers might also present antigens that trigger an immune response. 51 Our final set of results supports the hypothesis that ADCMV-transduced MDSCs can act as APCs and contribute to an immune reaction after adenoviral injection into skeletal muscle. The ADCMV-transduced MDSCs injected into mdx skeletal muscle functioned as APCs and triggered immunorejection, as indicated by an infiltration of CD4-and CD8-positive lymphocytes. The injection of ADMCK into the muscles that had been injected earlier with ADCMV-transduced MDSCs resulted in transient expression of the transgene and a severe immune response. In contrast, ADMCK-transduced MDSCs injected intramuscularly did not act as APCs. We observed a weaker immune response after subsequent direct injection of ADMCK into the same muscles (Figure 10c) .
In summary, our findings suggest that the use of a muscle-specific promoter can improve the outcome of both direct and ex vivo adenoviral gene transfer to skeletal muscle. In comparison with the use of a viral promoter, such as CMV, the use of a muscle-specific promoter in a direct gene transfer approach prevents transgene expression by host APCs and consequently leads to more persistent transgene expression. The use of a muscle-specific promoter can also reduce or delay the immune response elicited by ex vivo gene transfer based on MDSCs, since MDSCs transduced with a viral promoter in vitro can also act as APCs in vivo. These results may have important implications for the design of gene therapy approaches using MDSCs. AdNull contains the CMV promoter and SV40 poly-A sequences in place of the E1 region and does not express any transgenes. All AD vectors were generated by using shuttle vectors as described previously. 53, 54 The viruses generated by recombination between the shuttle vector and the AD DNA were plaque purified and propagated on 293 cells. At 2 days after vector administration, the viruses were purified from infected cells by using three freeze-thaw cycles followed by three successive bandings on CsCl gradients. The purified viruses were dialyzed against a buffer containing 10 mM Tris, pH 7.8, 150 mM NaCl, 10 mM MgCl 2 , and 3% sucrose and were stored at À801C until use. All viruses were tested and were found to have replication-competent AD levels of less than 1 in 1 Â 10 7 plaque-forming units (PFU).
Materials and methods
Virus injection
Six mice per viral vector were analyzed at every time point. The mice were anesthetized using Metafane (Mallinckrodt Veterinary, Mundelein, IL, USA), and the viral suspension (1 Â 10 7 PFU in 30 ml of Hanks' balanced salt solution (HBSS)) was subsequently injected percutaneously into both gastrocnemius muscles by using a Hamilton syringe with a 30-gauge needle. Mice receiving ADCMV or ADMCK injections were euthanized at 7, 14, 30, or 60 days after viral injection. The injected muscles were isolated, and half of the samples were used for luciferase assay, while the remaining samples were frozen in isopentane precooled in liquid nitrogen. Serial cryostat sections (10 mm) were subsequently analyzed by immunocytochemistry for luciferase expression.
Immunocytochemistry
In vitro. After being rinsed briefly with PBS, cells were fixed with cold methanol for 1 min. Cells then were blocked in 10% goat serum for 30 min. The primary antibodies used were polyclonal rabbit anti-luciferase (1:100; Abcam, Cambridge, UK) and anti-mouse dendritic cells-biotin conjugate (1:100; Leinco Technologies, Inc., St Louis, MO, USA). The subsequent antibodies were biotin-goat anti-rabbit (1:200; Chemicon, Temecula, CA, USA) followed by Cy3-streptavidin (1:1000; Sigma, St Louis, MO), for polyclonal rabbit anti-luciferase, and Cy3-streptavidin for anti-mouse dendritic cells-biotin conjugate.
In vivo. Muscle sections were fixed with cold acetone (À201C) for 2 min. After several rinses in TBS/Triton X-100, pH 7.4 (0.05 M Tris, 0.15 M NaCl, 1% Triton X-100), the cryosections were blocked with 10% goat serum for 30 min. In cases involving a secondary anti-mouse antibody, the mouse on mouse (MOM) kit (Vector Laboratories, Burlingame, CA, USA) was used. The sections then were incubated overnight at 41C in a humid chamber with the following primary antibodies: polyclonal rabbit anti-luciferase (1:100; Abcam), purified rat anti-mouse CD4 (1:100), purified rat anti-mouse CD8a After three rinses in TBS/Triton X-100, pH 7.4, the secondary antibodies biotin-goat anti-rabbit (1:200; Chemicon), biotin-goat anti-rat (1:400; Vector), biotin-goat anti-hamster (1:400; Vector), or anti-mouse-Cy3 (1:200; Sigma) were applied for 30 min at room temperature. The tertiary antibodies were FITC-streptavidin (1:200; Boehringer Mannheim, Indianapolis, IN, USA), peroxidase-conjugated streptavidin (1:800; DAKO, Glostrup, Denmark), or Cy3-streptavidin (1:1000; Sigma). The peroxidase activity (for CD4/CD8a) was revealed using 3,3 0 -diaminobenzidine (Sigma).
Double staining for CD11b and luciferase. After the initial block step, cryosections were stained with a primary antibody mix of rat anti-mouse CD11b (Chemicon) and rabbit anti-luciferase (Abcam), followed by biotin-goat anti-rat, Cy3-streptavidin, biotin-goat antirabbit, and FITC-streptavidin. To reveal any potential background generated by the primary and secondary antibodies, immunostaining controls were performed by using only primary or secondary antibodies followed by the tertiary antibodies. The conditions were also optimized to minimize the background staining. The number of CD4-and CD8-positive cells was quantified by using Northern Eclipse software (Empix Imaging, Inc., North Tonawanda, NY, USA). The section that had the highest number of positive cells was chosen for analysis. Counts were expressed as number of cells per section. Six muscles from six mice were counted.
Luciferase assay
The luciferase assay was conducted with the Luciferase Assay System (Promega, Madison, WI, USA) according to the instructions of the manufacturer. In brief, to establish a standard curve of light units versus relative enzyme concentrations, serial dilutions of luciferase (Promega) were made with 1 Â Reporter Lysis Buffer. Muscles were weighed, homogenized, and centrifuged. The supernatant was mixed with the Luciferase Assay Reagent, and the light produced was read in a luminometer (Monolight 2010, Analytical Luminescence Laboratory, San Diego, CA, USA).
Ex vivo approach using MDSCs
Primary muscle cells were isolated from normal newborn C57BL/10J mice by using the preplate technique, as described previously. 27, 43 MDSCs were transduced with either ADCMV or ADMCK at a multiplicity of infection of 50 (MOI ¼ 50). After 24 h transduction, 1 Â 10 5 cells were injected percutaneously into the gastrocnemius muscles of mdx mice (six mice per time point). Mice were killed 7, 14, 30, or 60 days after injection.
Serial injection of adenovirally transduced cells and ADs
MDSCs were transduced with ADCMV or ADMCK, as described above. A total of 1 Â 10 5 transduced cells were injected into the gastrocnemius muscles (six mice per time point). After 1 week, ADMCK (1 Â 10 7 PFU in 30 ml HBSS) was injected into the same muscles that previously had been injected with the transduced MDSCs.
Mice were killed 7, 14, and 30 days after the second injection.
Antigen-processing assay
A total of 1.5 Â 10 2 MDSCs were seeded in a 96-well plate. After 24 h, cells were transduced with ADCMV or ADMCK in HBSS for 3 h, and then were incubated with the proliferation medium overnight. A measure of 1 ml of DQ-Ovalbumin (Molecular Probes, Eugene, OR, USA) was added to each well and the transduced cells were incubated for 15 min at 371C. CD11b-positive cells were also incubated with 1 ml of DQ-Ovalbumin for 15 min at 371C as positive controls. After the incubation, the cells were washed with PBS and the same quantity of control cells was distributed into another 96-well plate. Mean fluorescence intensity (MFI) was determined at 30, 60, and 90 min by using a Wallac Victor 2 1420 Multilabel Counter (PerkinElmer Life Sciences, Wallac Oy, Turku, Finland).
Statistical analysis
Results are expressed as mean7standard deviations. Student's t-test was used to compare data between the two groups. Po0.05 was considered significant.
